Status:
UNKNOWN
Evaluation of Early Association of Terlipressin and Norepinephrine During Septic Shock; the TerliNor Study
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Conditions:
Septic Shock
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
In guidelines norepinephrine is the first line vasopressor recommended in case of septic shock. Use of vasopressin is recommended when norepinephrine fails to maintain a mean arterial pressure above 6...
Eligibility Criteria
Inclusion
- Older than 18 years
- Dose of norepinephrine greater than 0.3 μg / kg / min
- Lactate greater than 2.0 mmol / l
Exclusion
- A left heart failure objectified in ultrasound transthoracique by a fraction of left(awkward) ejection of the ventricle lower than 30 % either by thermodilution transpulmonaire with a cardiac index lower than 2,5 l / min / m2 after optimization of the volémie or a central venous saturation in oxygen ( SVcO2) lower than 60 % after optimization of the blood volume.
- Minors
- Pregnant
- Not having terlipressin allergy
- Not having excipient allergy
- A history known for recent acute coronary syndrome (\< 3mois)
- An acute coronary syndrome defined by an increase of the troponine and a rise of the segment ST in the electrocardiogram
Key Trial Info
Start Date :
July 27 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2019
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03336814
Start Date
July 27 2018
End Date
June 1 2019
Last Update
November 29 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assistance Publique - Hôpitaux de Marseille
Marseille, France, 13354